FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

0 Mga view· 09/07/23
OncLive® On Air
OncLive® On Air
0 Mga subscriber
0
Sa

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Magpakita ng higit pa

 0 Mga komento sort   Pagbukud-bukurin Ayon


Susunod